Pharmacyclics’ net loss was $10.96m for the fourth quarter ended 30 June 2011, compared to $6.84, for the same period in 2010.
The company’s loss from operations were $11m, compared to $6.86m for the same period in 2010.
For the full year ended 30 June 2011, the company reported a net revenues of $8.23m, compared to $9.31m for the same period in 2010.
The company has reported net loss of $35.2m for the full year ended 30 June 2011, as compared to $15.61m for the same period in the prior year.
Pharmacyclics’ loss from operations were $35.37m for the full year ended 30 June 2011, compared to $15.61m for the same period last year.
Pharmacyclics CEO and chairman of the board Bob Duggan said they plan to initiate their first Phase III trial for 32765 in this fiscal year ending 30 June 2012.